Research & Literature

Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases.

Scher JU, Littman DR, Abramson SB

Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(1)):35-45 doi:10.1002/art.39259.

The conundrum of juvenile psoriatic arthritis.

Ravelli A, Consolaro A, Schiappapietra B, Martini A

Clinical and experimental rheumatology 2015; (33(5 Suppl 93)):S40-3.

Etiology and Pathogenesis of Psoriatic Arthritis.

Barnas JL, Ritchlin CT

Rheumatic diseases clinics of North America 2015; (41(4)):643-63.

Melanocyte antigen triggers autoimmunity in human psoriasis.

Arakawa A, Siewert K, Stöhr J, et al.

The Journal of experimental medicine 2015; (212(13)):2203-12 doi:10.1084/jem.20151093.

Juvenile idiopathic arthritis-associated uveitis.

Clarke SL, Sen ES, Ramanan AV

Pediatric rheumatology online journal 2016; (14(1)):27 doi:10.1186/s12969-016-0088-2.

Diagnostic imaging of psoriatic arthritis. Part II: magnetic resonance imaging and ultrasonography.

Sudoł-Szopińska I, Pracoń G

Journal of ultrasonography 2016; (16(65)):163-74 doi:10.15557/JoU.2016.0018.

The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes.

Zisman D, Gladman DD, Stoll ML, et al.

The Journal of rheumatology 2017; (44(3)):342-351 doi:10.3899/jrheum.160717.

Uveitis and Juvenile Psoriatic Arthritis or Psoriasis.

Salek SS, Pradeep A, Guly C, et al.

American journal of ophthalmology 2018; (185()):68-74 doi:10.1016/j.ajo.2017.10.018.

Adiposity in Juvenile Psoriatic Arthritis.

Samad A, Stoll ML, Lavi I, et al.

The Journal of rheumatology 2018; (45(3)):411-418 doi:10.3899/jrheum.170598.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, et al.

Annals of the rheumatic diseases 2018; (77(6)):819-828 doi:10.1136/annrheumdis-2018-213030.

Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting.

Zisman D, Stoll ML, Butbul Aviel Y, Mellins ED

The Journal of rheumatology. Supplement 2018; (94()):11-16 doi:10.3899/jrheum.180131.

Prospective validation of the Juvenile Spondyloarthritis Disease Activity Index in children with enthesitis-related arthritis.

Zanwar A, Phatak S, Aggarwal A

Rheumatology (Oxford, England) 2018; (57(12)):2167-2171 doi:10.1093/rheumatology/key246.

Prospective Determination of the Incidence and Risk Factors of New-Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort.

Lee JJY, Duffy CM, Guzman J, et al.

Arthritis care & research 2019; (71(11)):1436-1443 doi:10.1002/acr.23783.

[Therapy of Psoriasis Arthritis Taking into Account New Treatment Options].

Ryser C, Ciurea A

Praxis 2018; (107(21)):1147-1153 doi:10.1024/1661-8157/a003090.

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Angeles-Han ST, Ringold S, Beukelman T, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(6)):864-877 doi:10.1002/art.40885.

Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities.

Brandon TG, Manos CK, Xiao R, et al.

Journal of psoriasis and psoriatic arthritis 2018; (3(4)):131-136 doi:10.1177/2475530318799072.

Patient-Reported Barriers at School for Children with Juvenile Idiopathic Arthritis.

Chomistek K, Johnson N, Stevenson R, et al.

ACR open rheumatology 2019; (1(3)):182-187 doi:10.1002/acr2.1023.

The Challenges and Opportunities of Classifying Childhood Arthritis.

Rumsey DG, Laxer RM

Current rheumatology reports 2020; (22(1)):4 doi:10.1007/s11926-020-0880-3.

A prospective study of novel disease activity indices for ankylosing spondylitis.

Sundaram TG, Muhammed H, Aggarwal A, Gupta L

Rheumatology international 2020; (40(11)):1843-1849 doi:10.1007/s00296-020-04662-w.

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis.

Rumsey DG, Lougee A, Matsouaka R, et al.

Arthritis care & research 2021; (73(7)):940-946 doi:10.1002/acr.24537.

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview.

Schinocca C, Rizzo C, Fasano S, et al.

Frontiers in immunology 2021; (12()):637829 doi:10.3389/fimmu.2021.637829.

Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience.

Karadağ ŞG, Demirkan FG, Koç R, et al.

Rheumatology international 2022; (42(1)):141-147 doi:10.1007/s00296-021-04854-y.

Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.

Ong MS, Ringold S, Kimura Y, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(10)):1910-1920 doi:10.1002/art.41892.

Diagnosis and treatment of uveitis associated with juvenile idiopathic arthritis.

Lazăr C, Spîrchez M, Ştefan M, et al.

Medicine and pharmacy reports 2021; (94(Suppl No 1)):S28-S32 doi:10.15386/mpr-2224.

Juvenile Idiopathic Arthritis Treatment Updates.

Onel K, Rumsey DG, Shenoi S

Rheumatic diseases clinics of North America 2021; (47(4)):545-563 doi:10.1016/j.rdc.2021.07.009.

Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis.

Chomistek K, Barnabe C, Naqvi SF, et al.

ACR open rheumatology 2022; (4(2)):142-151 doi:10.1002/acr2.11373.

Occurrence and Risk Factors of Uveitis in Juvenile Psoriatic Arthritis: Data From a Population-based Nationwide Study in Germany.

Baquet-Walscheid K, Rothaus K, Niewerth M, et al.

The Journal of rheumatology 2022; (49(7)):719-724 doi:10.3899/jrheum.210755.

Juvenile idiopathic arthritis.

Martini A, Lovell DJ, Albani S, et al.

Nature reviews. Disease primers 2022; (8(1)):5 doi:10.1038/s41572-021-00332-8.

Consensus Approach to a Treat-to-target Strategy in Juvenile Idiopathic Arthritis Care: Report From the 2020 PR-COIN Consensus Conference.

El Tal T, Ryan ME, Feldman BM, et al.

The Journal of rheumatology 2022; (49(5)):497-503 doi:10.3899/jrheum.210709.

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.

Brunner HI, Foeldvari I, Alexeeva E, et al.

Annals of the rheumatic diseases 2023; (82(1)):154-160 doi:10.1136/ard-2022-222849.

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.

Renton WD, Jung J, Palestine AG

The Cochrane database of systematic reviews 2022; (10()):CD013818 doi:10.1002/14651858.CD013818.pub2.

Bilateral Granulomatous Iridocyclitis Associated with Early-Onset Juvenile Psoriatic Arthritis.

Nieves-Ríos C, Requejo Figueroa GA, Ayala Rodríguez SC, et al.

Case reports in ophthalmological medicine 2022; (2022()):3990406 doi:10.1155/2022/3990406.

The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment.

Paroli M, Spadea L, Caccavale R, et al.

Medicina (Kaunas, Lithuania) 2022; (58(11)) doi:10.3390/medicina58111552.

Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate.

Naddei R, Rebollo-Giménez A, Burrone M, et al.

Journal of clinical medicine 2023; (12(1)) doi:10.3390/jcm12010367.

Non-Rheumatic Chronic Comorbidities in Children with Juvenile Idiopathic Arthritis.

Haşlak F, Guliyeva V, Hotaman B, et al.

Turkish archives of pediatrics 2023; (58(2)):212-219 doi:10.5152/TurkArchPediatr.2023.22303.

Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia.

Nossent JC, Kelty E, Keen H, et al.

Rheumatology international 2023; (43(7)):1357-1362 doi:10.1007/s00296-023-05318-1.

A comprehensive overview of juvenile idiopathic arthritis: From pathophysiology to management.

Bansal N, Pasricha C, Kumari P, et al.

Autoimmunity reviews 2023; (22(7)):103337 doi:10.1016/j.autrev.2023.103337.

The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis.

Low JM, Hyrich KL, Ciurtin C, et al.

Rheumatology (Oxford, England) 2024; (63(5)):1273-1280 doi:10.1093/rheumatology/kead370.

The Juvenile Spondyloarthritis Disease Activity Index Is a Useful Tool in Enthesitis-Related Arthritis: Real-Life Data.

Polat MC, Ekici Tekin Z, Çelikel E, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2023; (29(7)):309-315 doi:10.1097/RHU.0000000000002001.

Prevalence of ultrasound and clinical findings suggestive of inflammatory arthritis in children with skin psoriasis.

Coronel L, Gouze H, Gudu T, et al.

Rheumatology (Oxford, England) 2024; (63(5)):1391-1396 doi:10.1093/rheumatology/kead398.

Do the features of juvenile psoriatic arthritis change according to age? A comprehensive evaluation of the PeRA Research Group Registry.

Karadağ ŞG, Coskuner T, Demirkan FG, et al.

Rheumatology (Oxford, England) 2024; (63(SI2)):SI160-SI166 doi:10.1093/rheumatology/kead496.

Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward.

Bagri NK, Chew C, Ramanan AV

Paediatric drugs 2023; (25(6)):635-647 doi:10.1007/s40272-023-00594-7.

Current Validated Clinical and Patient Reported Disease Outcome Measures in Juvenile Idiopathic Arthritis.

Balay-Dustrude E, Shenoi S

Open access rheumatology : research and reviews 2023; (15()):189-206 doi:10.2147/OARRR.S261773.

Advancing the treatment of juvenile idiopathic arthritis.

Murray GM, Sen ES, Ramanan AV

The Lancet. Rheumatology 2021; (3(4)):e294-e305 doi:10.1016/S2665-9913(20)30426-4.

Safety and efficacy of biologic immunosuppressive treatment in juvenile idiopathic arthritis associated with inborn errors of immunity.

Accardo V, Pagnini I, Maccora I, et al.

Frontiers in pediatrics 2024; (12()):1353825 doi:10.3389/fped.2024.1353825.

Drug therapy in juvenile spondyloarthritis.

Srinivasalu H, Simpson J, Stoll ML

Current opinion in rheumatology 2024; (36(4)):295-301 doi:10.1097/BOR.0000000000001016.

HLA-Cw6 increases the risk of psoriasis and early onset before twenty-seven years of age among the Vietnamese population.

Pham NTU, Nguyen TV, Nguyen HT

Dermatology reports 2024; (16(2)):9854 doi:10.4081/dr.2023.9854.

Management of JIA associated uveitis.

Maccora I, Simonini G, Guly CM, Ramanan AV

Best practice & research. Clinical rheumatology 2024; (38(3)):101979 doi:10.1016/j.berh.2024.101979.

Magnetic resonance imaging of the musculoskeletal system in the diagnosis of rheumatic diseases in the pediatric population.

Ożga J, Mężyk E, Kmiecik W, et al.

Reumatologia 2024; (62(3)):196-206 doi:10.5114/reum/190262.

Evolution of treatment options for juvenile idiopathic arthritis.

Ren T, Guan JH, Li Y, et al.

World journal of orthopedics 2024; (15(9)):831-835 doi:10.5312/wjo.v15.i9.831.

Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data.

Qian Y, Schlachter L, Eckert D, et al.

Clinical pharmacology and therapeutics 2024; (116(6)):1635-1645 doi:10.1002/cpt.3441.

Exploring nailfold videocapillaroscopy in children with psoriatic arthritis: are there any hidden vascular signatures?

Menentoğlu B, Demirkan FG, Arık SD, et al.

Modern rheumatology 2026; (36(2)):290-298 doi:10.1093/mr/roaf079.

Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.

Weiss PF, Ruperto N, Quebe-Fehling E, et al.

The Journal of rheumatology 2026; (53(1)):85-94 doi:10.3899/jrheum.2025-0294.

Physical and Mechanical Therapies for Lower Limb Problems in Children With Juvenile Idiopathic Arthritis: A Systematic Review With Meta-Analysis.

Fellas A, Hawke F, Maarj M, et al.

Journal of foot and ankle research 2025; (18(4)):e70096 doi:10.1002/jfa2.70096.

Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study.

Kolkhidova ZA, Nikishina IP, Glukhova SI, et al.

World journal of clinical pediatrics 2025; (14(4)):108878 doi:10.5409/wjcp.v14.i4.108878.

Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).

Lam E, Berezny K, Bishop CJ, et al.

Rheumatology and therapy 2025; doi:10.1007/s40744-025-00820-3.